Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the MySalvia System, a minimally invasive implantable neuromodulation device, for preventing migraines in adults who have resistant migraine. This pivotal clinical trial focuses on adults aged 22 to 84 years who have chronic and difficult-to-treat migraine conditions, including migraines with or without aura. The study is randomized, double-blind, and controlled to thoroughly assess the devices impact. Participants will be randomly assigned to receive either the active MySalvia neurostimulator system or an active control. The device delivers mild electrical signals to targeted craniofacial nerves through implantable and non-implantable components. The study includes a 24-week treatment period where efficacy and safety are closely monitored. This trial excludes those using other neuromodulation devices or with certain implantable medical devices nearby. Throughout the study, participants will have regular assessments to monitor migraine frequency, severity, and any side effects. Evaluations include tracking changes in monthly migraine days and monitoring for adverse events related to the device. The primary outcomes focus on both the effectiveness of migraine prevention and the safety of the neurostimulator over the 24-week period. Participants will be involved for the duration of treatment and follow-up until study completion in 2031.
Actively Recruiting
Researchers are evaluating sacituzumab tirumotecan alone or combined with pembrolizumab to treat people with triple-negative breast cancer TNBC that is locally recurrent, unresectable, or metastatic and expresses PD-L1 at a combined positive score less than 10. The study aims to find out if these treatments help people live longer overall or delay cancer growth compared to chemotherapy chosen by their physician. This is a phase 3 randomized trial focused on treatment effectiveness and safety. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given intravenously every two weeks sacituzumab tirumotecan every two weeks plus pembrolizumab every six weeks for up to about two years or physicians choice chemotherapy including options like paclitaxel, nab-paclitaxel, gemcitabine plus carboplatin with varying schedules. Pre-medications such as antihistamines, acetaminophen, and steroids are given before sacituzumab tirumotecan infusions to reduce side effects. During the study, participants receive assigned treatments until disease progression, toxicity, or discontinuation. Researchers monitor progression-free survival and overall survival up to about 39 and 61 months respectively. They also assess response rates, duration of response, quality of life changes using questionnaires, and record adverse events over the study period. The trial follows participants for extended periods to evaluate long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating the drug VIM0423 in adults with Parkinsons disease who experience tremors that do not respond well to dopaminergic therapy. The study aims to determine if VIM0423 improves tremor symptoms, is well tolerated, and enhances daily function and quality of life. This Phase 2, multicenter, randomized, placebo-controlled trial will enroll up to 80 participants with Parkinsons tremor, a symptom that affects many and is often the most troubling for patients. Participants are divided into two groups Cohort 1 includes those on stable dopaminergic therapy with residual tremor, and Cohort 2 includes those who have never used dopaminergic therapies. Both cohorts are randomized to receive either VIM0423 or matching placebo, with doses up to five pills once daily for seven weeks. The study is triple-blinded, meaning neither participants nor investigators know the assigned treatment. The total participation lasts up to 12 weeks, including screening, treatment with tapering, and safety follow-up. During the study, participants attend six in-person visits for assessments including clinical evaluations, lab tests, and EKGs. They will wear a device to monitor tremor and complete self-assessments of tremor impact on daily activities. The primary outcome is change in Parkinsons disease symptoms measured by the Movement Disorder Society Unified Parkinsons Disease Rating Scale from baseline to Week 6. Secondary measures include clinician and patient global impressions, tremor-related daily living scales, and sleep assessments. Safety and adverse events are closely monitored throughout.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of VIM0423, an oral medication, in adults with isolated dystonia affecting two or more body regions. This rare movement disorder causes sustained muscle contractions leading to abnormal and sometimes twisting movements or postures. The study aims to determine if VIM0423 improves dystonia symptoms compared to a placebo, and if it can enhance daily function and quality of life. Participants will be randomly assigned to receive either VIM0423 or a matching placebo, taking up to six pills each evening before bed for 16 weeks. This Phase 2, double-blind, placebo-controlled trial includes a dose titration, maintenance, and tapering period. The study lasts up to 24 weeks and consists of 6 in-person visits, including screening, baseline assessments, treatment, and safety follow-up. Throughout the study, participants will undergo evaluations such as video assessments of dystonia symptoms, clinical laboratory tests, and EKGs. They will also complete self-assessments regarding the impact of dystonia on daily activities. Researchers will monitor adverse events and measure changes using the Burke-Fahn-Marsden Dystonia Rating Scale and other clinical global impression scales to assess symptom severity and improvements.
Actively Recruiting
Researchers are observing Parkinsons disease in patients aged 45 to 75 who continue to have movement symptoms despite taking standard Parkinsons medications. The study aims to better understand how the disease changes over time in this group, the challenges faced by patients and their care partners, and how current treatments are working in real life. Parkinsons disease causes movement problems like tremors, stiffness, slow movements, and balance difficulties, as well as non-motor symptoms such as mood changes and sleep issues. This study fills gaps left by earlier research that did not track patients long enough or collect comprehensive data. Participants will continue receiving their usual care without any changes, as no investigational treatments are given. Data will be collected from December 2025 to December 2032 and may include questionnaires, medical records, blood samples, skin biopsies, digital movement tracking devices, and reports from care partners. Both patients and their primary care partners may participate in the study. During the study, researchers will collect various types of information such as medical history, medications, movement and non-movement symptoms, genetic data, and the burden of care including psychological and economic aspects. Assessments will be done through doctor interviews, patient diaries, medical records, and digital monitoring. Participants may be followed for up to 5 years to provide a detailed understanding of disease progression and treatment effects.
Actively Recruiting
Healthy Volunteer
Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
1-10 of 16
1